SPNCN, activated by NIR, generates 1O2 for PDT and ICD, releasing CQ and NLG919 (IDO1 inhibitor) in the tumor. CQ enhances PDT and ICD, while NLG919 targets immunosuppressive tryptophan metabolism, boosting antitumor immunity and inhibiting tumor growth. This evidence concerns the gene IDO1 and neoplasm.